[HTML][HTML] Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells

L Zhang, Z Zhao, S Xu, M Tandon, CR LaValle… - Oncotarget, 2017 - ncbi.nlm.nih.gov
L Zhang, Z Zhao, S Xu, M Tandon, CR LaValle, F Deng, QJ Wang
Oncotarget, 2017ncbi.nlm.nih.gov
In prostate cancer, androgen/androgen receptor (AR) and their downstream targets play key
roles in all stages of disease progression. The protein kinase D (PKD) family, particularly
PKD1, has been implicated in prostate cancer biology. Here, we examined the cross-
regulation of PKD1 by androgen signaling in prostate cancer cells. Our data showed that the
transcription of PKD1 was repressed by androgen in androgen-sensitive prostate cancer
cells. Steroid depletion caused up regulation of PKD1 transcript and protein, an effect that …
Abstract
In prostate cancer, androgen/androgen receptor (AR) and their downstream targets play key roles in all stages of disease progression. The protein kinase D (PKD) family, particularly PKD1, has been implicated in prostate cancer biology. Here, we examined the cross-regulation of PKD1 by androgen signaling in prostate cancer cells. Our data showed that the transcription of PKD1 was repressed by androgen in androgen-sensitive prostate cancer cells. Steroid depletion caused up regulation of PKD1 transcript and protein, an effect that was reversed by the AR agonist R1881 in a time-and concentration-dependent manner, thus identifying PKD1 as a novel androgen-repressed gene. Kinetic analysis indicated that the repression of PKD1 by androgen required the induction of a repressor protein. Furthermore, inhibition or knockdown of AR reversed AR agonist-induced PKD1 repression, indicating that AR was required for the suppression of PKD1 expression by androgen. Downstream of AR, we identified fibroblast growth factor receptor substrate 2 (FRS2) and its downstream MEK/ERK pathway as mediators of androgen-induced PKD1 repression. In summary, PKD1 was identified as a novel androgen-suppressed gene and could be downregulated by androgen through a novel AR/FRS2/MEK/ERK pathway. The upregulation of prosurvival PKD1 by anti-androgens may contribute to therapeutic resistance in prostate cancer treatment.
ncbi.nlm.nih.gov